VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease (NCT02534844) | Clinical Trial Compass
CompletedPhase 2/3
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
United States56 participantsStarted 2015-10
Plain-language summary
Due to different study designs, the sponsor separated Part C into a separate registration (NCT04958642), leaving Parts A/B here in NCT02534844.
This study is to find out how safe and effective VTS-270 is for patients with Niemann-Pick Type C1 (NPC1) disease who have neurologic symptoms (listed under Keywords).
In Parts A/B, two out of every three patients will receive the study drug. The third patient will receive 1 to 2 small needle pricks at the location where the LP and IT injection is normally made (sham control).
In Part C, all participants will receive study drug, as described in the Part C registration record.
Start date for this record is the first day a participant was enrolled in Parts A/B. The trial is actually continuing until the last primary outcome measure of safety data are collected from Part C participants. The last primary outcome measure of safety, along with final adverse events results will be posted in the separate Part C registration record.
Who can participate
Age range4 Years – 21 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Had onset of neurological symptoms prior to 15 years of age
✓. Has confirmed diagnosis of NPC1 determined by either:
✓. two NPC1 mutations
✓. positive filipin staining and at least one NPC1 mutation
✓. vertical supranuclear gaze palsy (VSNGP) in combination with either: one NPC1 mutation, OR positive filipin staining or oxysterol levels consistent with NPC disease and no Niemann-Pick Type C2 (NPC2) Disease mutations
✓. Adult participant or parent/guardian has provided written informed consent, with assent collected from minors of appropriate age
✓. Is able to undergo a lumbar puncture (LP) and IT drug administration under conscious sedation or general anesthesia
✓. Has an NPC Clinical Severity Scale Score of 1 through 4, inclusive, in two or more of the following components: ambulation, fine motor skills, or swallowing; and has a score of 0 through 4 on the cognition component
Exclusion criteria
What they're measuring
1
Parts A/B: Change From Baseline to Week 52 in 4-Item Composite Score of Niemann Pick Type C Severity Scale (NPC-SS) Score
Timeframe: Baseline, Week 52
2
Parts A/B: Number of Participants Classified With Each Score on the Clinician Global Impression of Change (CGIC) at Week 52
. Has exclusion criteria as assessed by NPC Clinical Severity Scale:
✕. Unable to walk, wheelchair dependent (ambulation NPC score=5)
✕. Has need for a nasogastric tube to overcome swallowing difficulties (swallowing NPC score=5) unless used for supplemental feeding or administering medication
✕. severe dysmetria (fine motor score =5) or
✕. minimal cognitive function (cognition NPC score=5)
✕. Weighs less than 15 kg
✕. Has had prior treatment with intravenous 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) for NPC1 disease, unless the subject has undergone a minimum 3-month washout period prior to Study Day 0, or has had any prior intrathecal (IT) administration of HP-β-CD
✕. Is taking antipsychotics for treatment of psychosis; use of antipsychotic medication for treatment of other disorders (e.g., Attention Deficit Hyperactivity Disorder) will not exclude participation in this trial